| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| NEUTRAL | SELL | SELL | SELL | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 4.68▲ | 4.65▲ | 4.70▼ | 5.30▼ | 5.46▼ |
| MA10 | 4.66▲ | 4.68▲ | 4.86▼ | 5.53▼ | 4.70▼ |
| MA20 | 4.65▲ | 4.91▼ | 5.06▼ | 5.44▼ | 3.37▲ |
| MA50 | 4.81▼ | 5.23▼ | 5.51▼ | 4.25▲ | 3.08▲ |
| MA100 | 5.02▼ | 5.56▼ | 5.46▼ | 3.08▲ | 2.74▲ |
| MA200 | 5.23▼ | 5.44▼ | 5.45▼ | 2.86▲ | 4.28▲ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.019▲ | -0.007▼ | -0.031▼ | -0.187▼ | 0.267▲ |
| RSI | 48.529▼ | 35.761▼ | 31.970▼ | 43.600▼ | 59.464▲ |
| STOCH | 66.216 | 20.948 | 13.430▼ | 38.989 | 41.380 |
| WILL %R | -35.135 | -78.182▼ | -83.784▼ | -92.638▼ | -65.795 |
| CCI | 74.091 | -50.316 | -85.980 | -156.172▼ | 36.181 |
|
Monday, January 13, 2025 05:00 AM
“In addition, we expect to begin the pivotal THRIVE-3 study of intravenous (IV) Choline Chloride in the first half of 2025. We also expect data from our ongoing Phase 2 STARBORN-1 trial of TARA-002 in ...
|
|
Wednesday, January 08, 2025 05:25 AM
A live webcast of the presentation can be accessed by visiting the Events and Presentations section of the Company’s website: https://ir.protaratx.com. The webcast will be archived for a limited time ...
|
|
Wednesday, January 08, 2025 05:00 AM
NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 15/01/25 | 5.12 | 5.12 | 4.57 | 4.69 | 547,112 |
| 14/01/25 | 5.29 | 5.3721 | 5.01 | 5.03 | 231,565 |
| 13/01/25 | 5.47 | 5.47 | 5.10 | 5.31 | 264,944 |
| 10/01/25 | 5.71 | 5.94 | 5.45 | 5.56 | 372,132 |
| 08/01/25 | 6.04 | 6.04 | 5.55 | 5.91 | 435,377 |
| 07/01/25 | 5.89 | 6.155 | 5.81 | 5.98 | 629,107 |
| 06/01/25 | 6.20 | 6.20 | 5.75 | 5.85 | 509,429 |
| 03/01/25 | 5.66 | 6.15 | 5.645 | 6.14 | 563,369 |
| 02/01/25 | 5.27 | 5.71 | 5.24 | 5.58 | 347,933 |
| 31/12/24 | 5.35 | 5.525 | 5.035 | 5.28 | 329,983 |
|
|
||||
|
|
||||
|
|